Literature DB >> 21093544

Local repeated corticotropin-releasing factor infusion exacerbates anxiety- and fear-related behavior: differential involvement of the basolateral amygdala and medial prefrontal cortex.

E Y Bijlsma1, M L F van Leeuwen, K G C Westphal, B Olivier, L Groenink.   

Abstract

Increased central corticotropin-releasing factor (CRF) signaling has been associated with various psychiatric symptoms, including anxiety, depression and psychosis. CRF signaling in both the basolateral amygdala (BLA) and medial prefrontal cortex (mPFC) has been implicated in anxiety-like behavior. In addition, repeated activation of CRF receptors within the BLA induces a chronic anxious state. Here we studied the effects of local repeated CRF infusion in the BLA and mPFC on different forms of anxiety, as assessed during light-enhanced startle (LES, general anxiety) and acquisition of fear-potentiated startle (FPS, cue-conditioned fear). In addition, as CRF has been implicated in sensorimotor gating, prepulse inhibition (PPI) was assessed to determine if local CRF infusion within the BLA or mPFC would interfere with the processing of sensory information. To this end, canulas were placed bilaterally in either the BLA or mPFC of Wistar rats. After recovery, animals were infused with h/rCRF (200 ng/side) or vehicle for five consecutive days. Long term effects of local CRF infusion on LES and acquisition of FPS were measured 4 and 10 days post-treatment, respectively. In addition, the acute (day 1), sub-chronic (day 5) and long-term (7 days post treatment) effects on PPI were measured in the same animals. A clear regional differentiation was found on the long lasting effect of CRF on anxiety-like behavior: infusion into the BLA only enhanced acquisition of FPS, whereas infusion into the mPFC only enhanced LES. Sub-chronic CRF infusion into the BLA, but not the mPFC, disrupted PPI. This disturbed PPI was normalized 7 days post-treatment. Together, the current study shows that local repeated CRF receptor activation in the BLA and mPFC is differentially involved in anxiety- and fear-related behavior. In addition, the BLA may be involved in CRF-induced sensorimotor gating deficits. The absence of a long-term effect on these PPI deficits suggests that lasting activation of CRF receptors is a prerequisite for CRF-mediated effects on sensorimotor gating. The long-term effects of repeated CRF infusion on LES and acquisition of FPS on the other hand, show that in case of anxiety-related processes repeated CRF infusion may have lasting effects.
© 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21093544     DOI: 10.1016/j.neuroscience.2010.11.026

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  18 in total

1.  Interactions between corticotropin-releasing factor and the serotonin 1A receptor system on acoustic startle amplitude and prepulse inhibition of the startle response in two rat strains.

Authors:  Lisa H Conti
Journal:  Neuropharmacology       Date:  2011-08-02       Impact factor: 5.250

2.  Enduring sensorimotor gating abnormalities following predator exposure or corticotropin-releasing factor in rats: a model for PTSD-like information-processing deficits?

Authors:  Vaishali P Bakshi; Karen M Alsene; Patrick H Roseboom; Elenora E Connors
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

3.  Polymorphism in the corticotropin-releasing factor receptor 1 (CRF1-R) gene plays a role in shaping the high anxious phenotype of Marchigian Sardinian alcohol-preferring (msP) rats.

Authors:  Andrea Cippitelli; Lydia O Ayanwuyi; Estelle Barbier; Esi Domi; Jose M Lerma-Cabrera; Francisca Carvajal; Giulia Scuppa; Hongwu Li; Massimo Ubaldi; Markus Heilig; Marisa Roberto; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2014-09-27       Impact factor: 4.530

Review 4.  Sex-biased stress signaling: the corticotropin-releasing factor receptor as a model.

Authors:  Rita J Valentino; Debra Bangasser; Elisabeth J Van Bockstaele
Journal:  Mol Pharmacol       Date:  2012-12-13       Impact factor: 4.436

Review 5.  Neuropeptide Y and posttraumatic stress disorder.

Authors:  R Sah; T D Geracioti
Journal:  Mol Psychiatry       Date:  2012-07-17       Impact factor: 15.992

Review 6.  The Deakin/Graeff hypothesis: focus on serotonergic inhibition of panic.

Authors:  Evan D Paul; Philip L Johnson; Anantha Shekhar; Christopher A Lowry
Journal:  Neurosci Biobehav Rev       Date:  2014-03-21       Impact factor: 8.989

Review 7.  Region-specific roles of the corticotropin-releasing factor-urocortin system in stress.

Authors:  Marloes J A G Henckens; Jan M Deussing; Alon Chen
Journal:  Nat Rev Neurosci       Date:  2016-09-02       Impact factor: 34.870

8.  The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle.

Authors:  Christian Grillon; Elizabeth Hale; Lynne Lieberman; Andrew Davis; Daniel S Pine; Monique Ernst
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

9.  The effect of anxiety on respiratory sensory gating measured by respiratory-related evoked potentials.

Authors:  Pei-Ying S Chan; Andreas von Leupoldt; Margaret M Bradley; Peter J Lang; Paul W Davenport
Journal:  Biol Psychol       Date:  2012-07-07       Impact factor: 3.251

10.  The role of PKC signaling in CRF-induced modulation of startle.

Authors:  M Toth; J E Gresack; R L Hauger; A L Halberstadt; V B Risbrough
Journal:  Psychopharmacology (Berl)       Date:  2013-05-31       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.